The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to demonstrate room-temperature-stable, dry powder inhalable influenza vaccines represent as an innovative, next generation technology to promote the health and welfare of the American public by eliminating the existing pain points of current influenza vaccines. The global influenza vaccine market size is projected to increase to $17.77 billion by 2032. Therefore, the demand for innovative vaccines against seasonal respiratory viruses remains a high priority. These dry powder vaccines introduce a transformative innovation – induction of durable protective immunity that targets both the upper and lower airways via nasal delivery and removing the cold chain due to room-temperature shelf stability, thereby lowering vaccine costs and wastage. This outcome can result in cost savings of up to 80%. The economic and social benefits of this vaccine technology will lead to achieving and maintaining a significant market share of the flu vaccine market. Additionally, this technology’s plug-and-play capability allows swapping pathogen-specific proteins and creating new inhalable room-temperature-stable vaccines for other respiratory pathogens. Altogether, this advance will significantly lower storage costs while improving our nation’s strategic preparedness in stockpiling vaccines against circulating disease, emerging threats, or biowarfare agents. This Small Business Technology